Literature DB >> 7614646

Secondary hyperparathyroidism shortens the action of vecuronium in patients with chronic renal failure.

K Takita1, Y Goda, O Kemmotsu, H Mashio, A Okuyama, Y Ito, H Sakamoto, H Kawahigashi.   

Abstract

The authors studied the duration of action of vecuronium in 15 patients with normal renal function and 40 patients with chronic renal failure to evaluate the effect of secondary hyperparathyroidism on the action of vecuronium. The patients were divided into four groups: 15 patients with normal renal function (Group A); nine patients with chronic renal failure who did not need haemodialysis (Group B); 15 anephric patients who did not require parathyroidectomy (Group C); and 16 anephric patients who underwent parathyroidectomy because of severe secondary hyperparathyroidism (Group D). The ratio of the height of the first twitch (T1) to the baseline value before vecuronium administration was measured by an electromyogram. Baseline T1 was obtained after anaesthesia induction with thiamylal iv. The time to 10% recovery of the first twitch (REC 10) after administration of vecuronium 0.12 mg.kg-1 iv was measured in each group. Anaesthesia was maintained with isoflurane and nitrous oxide in oxygen, and supplemented with fentanyl iv. Patients in Group D showed shorter REC 10 (51 +/- 4 min) than those in Groups B (71 +/- 6 min) and C (80 +/- 10 min) (P < 0.05), but similar REC 10 to patients in Group A (37 +/- 4 min). These results suggest that the duration of action of vecuronium in anephric patients with secondary hyperparathyroidism is shorter than in those without secondary hyperparathyroidism.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7614646     DOI: 10.1007/BF03015484

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  12 in total

1.  Contribution of high concentrations of PTH(1-34) to muscle weakness in uremia by suppression of guanidinoacetic acid synthesis.

Authors:  M Takeda; M Kubota; I Kiyatake; Y Tomino; H Koide
Journal:  Nephron       Date:  1991       Impact factor: 2.847

2.  Prolonged neuromuscular blockade after long-term administration of vecuronium in two critically ill patients.

Authors:  V Segredo; M A Matthay; M L Sharma; L D Gruenke; J E Caldwell; R D Miller
Journal:  Anesthesiology       Date:  1990-03       Impact factor: 7.892

3.  The pharmacodynamics and pharmacokinetics of vecuronium in patients anesthetized with isoflurane with normal renal function or with renal failure.

Authors:  D P Lynam; R Cronnelly; K P Castagnoli; P C Canfell; J Caldwell; J Arden; R D Miller
Journal:  Anesthesiology       Date:  1988-08       Impact factor: 7.892

4.  Abnormal responses to muscle relaxants in a patient with primary hyperparathyroidism.

Authors:  S Al-Mohaya; M Naguib; M Abdelatif; H Farag
Journal:  Anesthesiology       Date:  1986-11       Impact factor: 7.892

5.  Renal and biliary elimination of vecuronium (ORG NC 45) and pancuronium in rats.

Authors:  R A Upton; T L Nguyen; R D Miller; N Castagnoli
Journal:  Anesth Analg       Date:  1982-04       Impact factor: 5.108

6.  Pharmacokinetics of Org NC45 (norcuron) in patients with and without renal failure.

Authors:  M R Fahey; R B Morris; R D Miller; T L Nguyen; R A Upton
Journal:  Br J Anaesth       Date:  1981-10       Impact factor: 9.166

7.  Comparison of vecuronium, atracurium and tubocurarine in normal patients and in patients with no renal function.

Authors:  J M Hunter; R S Jones; J E Utting
Journal:  Br J Anaesth       Date:  1984-09       Impact factor: 9.166

8.  [The action of atracurium and vecuronium in chronically hemodialyzed patients].

Authors:  J Link; G Papadopoulos; P Heine; J Wolter
Journal:  Anaesthesist       Date:  1993-01       Impact factor: 1.041

9.  [Vecuronium-induced neuromuscular blockade in two patients with hyperparathyroidism and a patient with hypoparathyroidism].

Authors:  A Kirita; H Iwasaki; S Fujita; H Narimatsu; Y Nishikawa; A Namiki
Journal:  Masui       Date:  1992-01

10.  Pharmacodynamics of vecuronium in patients with and without renal failure: a meta-analysis.

Authors:  C Beauvoir; P Peray; J P Daures; J L Peschaud; F D'Athis
Journal:  Can J Anaesth       Date:  1993-08       Impact factor: 5.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.